Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | New Epigenetic Kits for Demethylase and Methyltransferase Drug Discovery from BPS BioscienceBPS Bioscience, Inc. (“BPS”) announces new kits for screening inhibitors of the histone demethylases FBXL10 & FBXL11 and the histone methyltransferase SETDB1. These unique kits join a large portfolio of kits and proteins for epigenetic research.
SETDB1, also known as ESET or KMT1E, is a histone methyltransferase that specifically methylates lysine 9 on histone H3 (H3K9), the highly studied epigenetic modification associated with transcriptional repression. SETDB1 activity is required to maintain embryonic stem cells and neurons in an undifferentiated state. The SETDB1 gene is amplified in melanoma, and SETDB1 hypermethylation promotes melanoma formation and growth, making SETDB1 inhibition a promising therapeutic target for melanoma and other human cancers. Hypermethylation of H3K9 is also linked to Huntington Disease; downregulation of SETDB1 activity in transgenic mice ameliorated the behavioral and neuropathological phenotype and extended survival by an astounding 40%*. Because of the critical importance of histone methylation in cell proliferation, differentiation, senescence, and tumorigenesis, researchers are actively seeking small molecule regulators of histone methylation as targets for drug discovery. BPS is the first company to offer assay kits to screen for modulators of FBXL10, FBXL11, and SETDB1. The assays are simple, sensitive, homogeneous, non-radioactive, and suitable for high throughput applications. In addition to offering these unique assay kits, BPS offers methyltransferase and demethylase screening/profiling services, as well as the individual recombinant proteins, substrates, and H3K9 and H3K36 methylation- To learn more about BPS’s demethylase and methyltransferase products, please visit http://bpsbioscience.com/ *Ryu, H., et al. Proc Natl Acad Sci U S A. (http://www.ncbi.nlm.nih.gov/ About BPS Bioscience, Inc. Headquartered in San Diego, California, BPS Bioscience, Inc. is the leading manufacturer of epigenetic enzymes and assay kits for life science research, including HDACs, histone demethylases, DNA and histone methyltransferases, bromodomains, PARPs, acetyltransferases, methyl lysine readers, and more. BPS also offers compound screening and profiling services and cell based assays for epigenetic drug discovery. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide, and it continues to expand its portfolio of innovative drug discovery products. By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases. Visit BPS’s website for more information: End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|